HCM
CLDX icon

Highlander Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Highlander Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$839 Hold
20
– – ﹤0.01% 883
2023
Q4 		$793 Hold
20
– – ﹤0.01% 914
2023
Q3 		$1K Buy
+20
New +$627 ﹤0.01% 859
2014
Q4 		– Sell
-467
Closed -$90.7K – 850
2014
Q3 		$90.7K Buy
+467
New +$102K 0.09% 250

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Highlander Capital Management's CLDX Position: Q1 2024 in Review

Highlander Capital Management held its Celldex Therapeutics (CLDX) position steady in Q1 2024 at 20 shares worth $839. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Highlander Capital Management first reported a position in CLDX in Q3 2014 and has held it in 4 quarters since. The position peaked at $90.7K in Q3 2014. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.

  • Highlander Capital Management held 20 shares of Celldex Therapeutics worth $839 as of Q1 2024.
  • Highlander Capital Management left its Celldex Therapeutics share count unchanged in Q1 2024.
  • Celldex Therapeutics made up ﹤0.01% of Highlander Capital Management's portfolio in Q1 2024, its #883 holding.
  • Highlander Capital Management first reported a position in Celldex Therapeutics in Q3 2014 and has held it in 4 quarters since.
  • Highlander Capital Management's Celldex Therapeutics position peaked at $90.7K in Q3 2014.
  • 197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.

Based on Highlander Capital Management's 13F filing for Q1 2024, filed 20 May 2024.